| Industry | 制造业 | ||||||||||||||||||||||||
| Company Introduction | 山西仟源医药集团股份有限公司是一家集研发、生产、营销为一体的医药上市企业，集团总部位于上海。公司前身山西仟源制药有限公司成立于2005年3月23日，从仅有100多名员工，2个主打产品的小型制药企业发展至今，集团现有雇员1600多名，提供的产品和服务遍及全国34个省级行政区，并逐步将业务向国际市场及精准医疗等领域延伸。公司于2010年6月变更名称为山西仟源制药股份有限公司，2011年8月19日在深交所创业板成功上市。2014年9月，公司更名为山西仟源医药集团股份有限公司，证券简称“仟源医药”（股票代码：300254）。 发展过程中，仟源医药凭借敏锐的市场嗅觉和战略眼光，不断通过外延式并购和投资等手段，帮助企业迅速抓取市场机遇，优化产品结构，实现了跨越式发展。截至目前，集团旗下拥有杭州保灵药业、浙江海力生制药、江苏嘉逸医药、杭州恩氏基因、四川仟源中药、无锡联合利康检验以及西藏仟源等10家全资和控股子公司，集团总部和营销事业部设在上海。 仟源医药拥有现代化的生产基地、分销中心和高水准的研发团队，在化学合成药物、生物药、天然药物、原料药中间体、中成药、中药饮片、营养保健品、医药流通等多个领域具有雄厚的产业基础，致力于打造医药行业全产业链的大型医药健康产业集团。 为适应医药行业形势的不断变化，着眼未来长远发展，仟源医药于2020年重新制定了“以高端制药为核心，精准医疗和保健食品为两翼”的发展战略，依托集团高级药物研究院及成熟的营销体系，不断提升仟源医药的核心竞争力与市场地位。仟源人将继续秉承“Challenge&Young”的企业精神和“专业、诚信、进取、分享”的核心价值观，以实现“医药百强企业、百亿市值和健康稳定持续发展的百年企业”为目标，与世界一同进步，让健康更加简单！ | ||||||||||||||||||||||||
| Main Business | 医药、保健食品的研发、生产、销售及医学诊断、基因保存等医疗健康服务及商业服务等。 | ||||||||||||||||||||||||
| Legal Representative | 赵群 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 俞俊贤 | ||||||||||||||||||||||||
| Solicitors | 国浩律师（上海）事务所 | ||||||||||||||||||||||||
| Auditors | 立信中联会计师事务所（特殊普通合伙） | ||||||||||||||||||||||||
| Tel No | 0352-6116426 | ||||||||||||||||||||||||
| Fax No | 0352-6116452 | ||||||||||||||||||||||||
| Website | www.cy-pharm.com | ||||||||||||||||||||||||
| stock@cy-pharm.com;xyy1934@163.com | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 19/08/2011 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ 0.175 | ||||||||||||||||||||||||
| DPS(RMB)* | -- | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 1.381 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 2.196B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |